A Simple Prognostic Scoring System for Hepatocellular Carcinoma Treated with DEB-TACE
Bo Jiang1, Dong Lu2, Jiaying Dai3
1Department of Interventional Ultrasound, The Second Affiliated Hospital, Anhui Medical University, Hefei, Anhui, 230022, People's Republic of China.
Journal of Hepatocellular Carcinoma
|July 15, 2024
Summary
A new scoring system, DTH, predicts outcomes for hepatocellular carcinoma (HCC) patients receiving drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE). This tool aids treatment planning for better HCC management.
Area of Science:
- Hepatobiliary oncology
- Interventional radiology
- Clinical prognostication
Background:
- Hepatocellular carcinoma (HCC) is a primary liver malignancy.
- Drug-eluting bead-transcatheter arterial chemoembolization (DEB-TACE) is a key treatment modality for HCC.
- Predictive models are needed to optimize DEB-TACE efficacy.
Purpose of the Study:
- To develop and validate a prognostic scoring system for predicting DEB-TACE efficacy in HCC.
- To identify independent factors influencing overall survival (OS) in HCC patients treated with DEB-TACE.
Main Methods:
- Retrospective analysis of 230 HCC patients treated with DEB-TACE across six centers.
- Development of a predictive score based on independent risk factors for OS.
- Validation of the score against existing HCC staging systems.
Main Results:
- Tumor count, albumin-bilirubin levels, alpha-fetoprotein, and portal vein thrombus grade were significant OS predictors.
- The developed DEB-TACE treatment of HCC (DTH) scoring system stratified patients into low, medium, and high-risk groups.
- The DTH score demonstrated superior predictive accuracy for OS compared to other HCC staging systems.
Conclusions:
- The DTH-HCC scoring system accurately predicts outcomes for HCC patients undergoing DEB-TACE.
- This prognostic tool can assist in initial treatment planning and decision-making for DEB-TACE in HCC.
